Blocknomi
TLDR BeOne’s liver cancer drug posts a 36% response rate in a Phase 1 clinical study. BGB-B2033 shows a 74.1% six-month response durability rate at its target dose. BeOne’s lung…
Related articles
-
ZachXBT Traces Over $20M in Illicit Flows Through FreedomXMR on Hyperliquid
BlockchainReporter Published 21.10.2026 03:54
-
MSCI To Move Forward With Proposal That Could Exclude Strategy From Index
Bitcoin Magazine Published 16.10.2026 16:32
-
A Michigan Doorstop Was Authenticated as a $100,000 Rock From Space
Bitcoin.com Published 14.10.2026 05:30
-
Monero (XMR), Stellar (XLM), Bitcoin (BTC) and Hyperliquid (HYPE) Price Analysis for October 23: Volatility Is Back, but Market Is Depressed
U.Today Published 23.10.2026 04:55
-
The Largest XRP Treasury Goes Public, but Its Nasdaq Debut Ends in Red
BeInCrypto Published 12.10.2026 22:00
-
Ledger Investigates Crypto Theft Reports
U.Today Published 09.10.2026 14:53
-
UK Sanctions Crypto Exchanges Over Suspected Russia-Linked Evasion
Bitcoin.com Published 09.10.2026 03:05
-
Broadcom (AVGO) Stock: Secures Landmark 10-Year Cloud Deal With NTT DOCOMO
Blocknomi Published 20.10.2026 20:15